合縱科技(300477.SZ):赫利俄斯擬受讓湖南雅城4.43%股權
格隆匯1月19日丨合縱科技(300477.SZ)公佈,為減少關聯交易、避免利益輸送,優化標的公司湖南雅城新能源股份有限公司(簡稱“湖南雅城”)股權結構,提升對標的公司的控制權,公司的全資子公司赫利俄斯擬受讓南京合聚所持有湖南雅城4.43%的股權。赫利俄斯以5776.26萬元受讓南京合聚所持有的湖南雅城24,990,000股股份,佔湖南雅城總股本的4.43%,上述交易對價的資金來源為赫利俄斯自有或自籌資金。本次交易完成後,赫利俄斯持有湖南雅城股權的比例將由62.07%變更為66.50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.